{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:54:15Z","timestamp":1783004055528,"version":"3.54.5"},"reference-count":109,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy in Iasi, Romania"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Type 2 Diabetes (T2D) is a complex metabolic disorder that affects multiple organs, leading to severe complications in the pancreas, kidneys, liver, and heart. Prolonged hyperglycemia, along with oxidative stress and chronic inflammation, plays a crucial role in accelerating tissue damage, significantly increasing the risk of diabetic complications such as nephropathy, hepatopathy, and cardiovascular disease. This review evaluates the protective effects of various antidiabetic treatments on organ tissues affected by T2D, based on findings from experimental animal models. Metformin, a first-line antidiabetic agent, has been widely recognized for its ability to reduce inflammation and oxidative stress, thereby mitigating diabetes-induced organ damage. Its protective role extends beyond glucose regulation, offering benefits such as improved mitochondrial function and reduced fibrosis in affected tissues. In addition to traditional therapies, new classes of antidiabetic drugs, including sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists not only improve glycemic control but also exhibit nephroprotective and cardioprotective properties by reducing glomerular hyperfiltration, oxidative stress, and inflammation. Similarly, GLP-1 receptor agonists have been associated with reduced hepatic steatosis and enhanced cardiovascular function. Preclinical studies suggest that tirzepatide, a dual GLP-1\/gastric inhibitory polypeptide receptor agonist may offer superior metabolic benefits compared to conventional GLP-1 agonists by improving \u03b2-cell function, enhancing insulin sensitivity, and reducing fatty liver progression. Despite promising preclinical results, differences between animal models and human physiology pose a challenge. Further clinical research is needed to confirm these effects and refine treatment strategies. Future T2D management aims to go beyond glycemic control, emphasizing organ protection and long-term disease prevention.<\/jats:p>","DOI":"10.3390\/ph18050670","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:35:13Z","timestamp":1746185713000},"page":"670","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the Protective Effects of Traditional Antidiabetic Medications and Novel Antihyperglycemic Agents in Diabetic Rodent Models"],"prefix":"10.3390","volume":"18","author":[{"given":"Cosmin Gabriel","family":"Tartau","sequence":"first","affiliation":[{"name":"Department of Morphofunctional Sciences I, Faculty of Medicine, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8516-9766","authenticated-orcid":false,"given":"Ianis Kevyn Stefan","family":"Boboc","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-3811","authenticated-orcid":false,"given":"Liliana","family":"Mititelu-Tartau","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8089-1787","authenticated-orcid":false,"given":"Maria","family":"Bogdan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Rozalina","family":"Buca","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana Lacramioara","family":"Pavel","sequence":"additional","affiliation":[{"name":"Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, \u2018Dunarea de Jos\u2019 University, 800010 Galati, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8228-104X","authenticated-orcid":false,"given":"Cornelia","family":"Amalinei","sequence":"additional","affiliation":[{"name":"Department of Morphofunctional Sciences I, Faculty of Medicine, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Guo, H., Wu, H., and Li, Z. (2023). The pathogenesis of diabetes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24086978"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Durruty, P., Sanzana, M., and Sanhueza, L. (2019). Pathogenesis of Type 2 Diabetes Mellitus, IntechOpen.","DOI":"10.5772\/intechopen.83692"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/db16-0806","article-title":"Differentiation of diabetes by pathophysiology, natural history, and prognosis","volume":"66","author":"Skyler","year":"2017","journal-title":"Diabetes"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hayden, M.R. (2023). Overview and new insights into the metabolic syndrome: Risk factors and emerging variables in the development of type 2 diabetes and cerebrocardiovascular disease. Medicina, 59.","DOI":"10.20944\/preprints202302.0115.v1"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhao, X., An, X., Yang, C., Sun, W., Ji, H., and Lian, F. (2023). Crucial role and mechanism of insulin resistance in metabolic disease. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1149239"},{"key":"ref_6","first-page":"3826","article-title":"A study of histopathological changes in diabetic and nondiabetic cadaveric pancreas with respect to diabetic status","volume":"15","author":"Baro","year":"2024","journal-title":"J. Cardiovasc. Dis. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ahima, R.S. (2023). Type 2 Diabetes-etiology, epidemiology, pathogenesis, treatment. Metabolic Syndrome, Springer.","DOI":"10.1007\/978-3-031-40116-9"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rojas, A., Lindner, C., Schneider, I., Gonzalez, I., and Uribarri, J. (2024). The RAGE axis: A relevant inflammatory hub in human diseases. Biomolecules, 14.","DOI":"10.3390\/biom14040412"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2478\/enr-2024-0007","article-title":"Advanced glycation end products of dietary origin and their association with inflammation in diabetes\u2014A minireview","volume":"58","author":"Pedreanez","year":"2024","journal-title":"Endocr. Regul."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10020-024-00824-9","article-title":"An update on chronic complications of diabetes mellitus: From molecular mechanisms to therapeutic strategies with a focus on metabolic memory","volume":"30","author":"Yang","year":"2024","journal-title":"Mol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Liu, H., Wang, X., Gao, H., Yang, C., and Xie, C. (2023). Physiological and pathological characteristics of vascular endothelial injury in diabetes and the regulatory mechanism of autophagy. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1191426"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/febs.16306","article-title":"Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk","volume":"290","author":"Sanches","year":"2023","journal-title":"FEBS J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s43856-023-00363-0","article-title":"Impact of individual and environmental factors on dietary or lifestyle interventions to prevent type 2 diabetes development: A systematic review","volume":"3","author":"Bodhini","year":"2023","journal-title":"Commun. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00015.2017","article-title":"Interorgan metabolic crosstalk in human insulin resistance","volume":"98","author":"Gancheva","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Casado, M.E., Collado-P\u00e9rez, R., Frago, L.M., and Barrios, V. (2023). Recent advances in the knowledge of the mechanisms of leptin physiology and actions in neurological and metabolic pathologies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021422"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"F519","DOI":"10.1152\/ajprenal.00105.2023","article-title":"Loss of endothelial glucocorticoid receptor accelerates organ fibrosis in db\/db mice","volume":"325","author":"Srivastava","year":"2023","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","article-title":"Diabetic vascular diseases: Molecular mechanisms and therapeutic strategies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1210\/endrev\/bnad030","article-title":"Protective factors and the pathogenesis of complications in diabetes","volume":"45","author":"Yu","year":"2023","journal-title":"Endocr. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2147\/DMSO.S390857","article-title":"The interaction between age and risk factors for diabetes and prediabetes: A community-based cross-sectional study","volume":"16","author":"Yan","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4103\/ajm.ajm_53_20","article-title":"Pathophysiology of diabetes: An overview","volume":"10","author":"Banday","year":"2020","journal-title":"Avicenna J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e35285","DOI":"10.1097\/MD.0000000000035285","article-title":"Vascular complications of diabetes: A narrative review","volume":"102","author":"Lu","year":"2023","journal-title":"Medicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7748\/ns.2023.e11933","article-title":"An overview of complications associated with type 1 and type 2 diabetes","volume":"38","author":"Wilson","year":"2023","journal-title":"Nurs. Stand."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e142243","DOI":"10.1172\/JCI142243","article-title":"Pharmacological treatment of hyperglycemia in type 2 diabetes","volume":"131","author":"Taylor","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104158","DOI":"10.1016\/j.lpm.2022.104158","article-title":"Clinical pharmacology of antidiabetic drugs: What can be expected of their use?","volume":"52","author":"Scheen","year":"2023","journal-title":"Presse Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"155332","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of type 2 diabetes: An update and future directions","volume":"137","author":"DeMarsilis","year":"2022","journal-title":"Metabolism"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/endocrines5010005","article-title":"Is tirzepatide the new game changer in type 2 diabetes?","volume":"5","author":"Lisco","year":"2024","journal-title":"Endocrines"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/dom.15446","article-title":"Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo","volume":"26","author":"Ma","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.biopha.2018.07.157","article-title":"Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity","volume":"107","author":"Giri","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hu, Q., Chen, Y., Deng, X., Li, Y., Ma, X., Zeng, J., and Zhao, Y. (2023). Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation. Biomed. Pharmacother., 159.","DOI":"10.1016\/j.biopha.2023.114252"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.34067\/KID.0000000000000247","article-title":"Impact of diabetic lesions on pathology, treatment, and outcomes of glomerular diseases","volume":"4","author":"Kim","year":"2023","journal-title":"Kidney"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Patel, S., Srivastava, S., Singh, M.R., and Singh, D. (2019). Mechanistic insight into diabetic wounds: Pathogenesis, molecular targets and treatment strategies to pace wound healing. Biomed. Pharmacother., 112.","DOI":"10.1016\/j.biopha.2019.108615"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kim, K.-S., Lee, J.-S., Park, J.-H., Lee, E.-Y., Moon, J.-S., Lee, S.-K., Lee, J.-S., Kim, J.-H., and Kim, H.-S. (2021). Identification of novel biomarker for early detection of diabetic nephropathy. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050457"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12041-020-01196-9","article-title":"Dapagliflozin, a sodium glucose cotransporter 2 inhibitors, protects cardiovascular function in type-2 diabetic murine model","volume":"99","author":"Saleh","year":"2020","journal-title":"J. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41420-023-01553-4","article-title":"Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions","volume":"9","author":"Huo","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/dsi23-0015","article-title":"Nonalcoholic fatty liver disease in diabetes: A call to action","volume":"37","author":"Cusi","year":"2024","journal-title":"Diabetes Spectr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"106358","DOI":"10.1016\/j.phrs.2022.106358","article-title":"Inside the diabetic brain: Insulin resistance and molecular mechanism associated with cognitive impairment and its possible therapeutic strategies","volume":"182","author":"Dutta","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_40","first-page":"e43697","article-title":"Advances in the management of diabetes mellitus: A focus on personalized medicine","volume":"15","author":"Sugandh","year":"2023","journal-title":"Cureus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1002\/hsr2.1642","article-title":"Transform diabetes care with precision medicine","volume":"6","author":"Kannan","year":"2023","journal-title":"Health Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1111\/bcp.14674","article-title":"Precision medicine in diabetes-Finally some light at the end of the tunnel?","volume":"87","author":"Raj","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ahmad, E., Sargeant, J.A., Zaccardi, F., Khunti, K., Webb, D.R., and Davies, M.J. (2020). Where does metformin stand in modern day management of type 2 diabetes?. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120427"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.15663","article-title":"Metformin: Therapeutic profile in the treatment of type 2 diabetes","volume":"26","author":"Bailey","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1007\/s10238-023-01051-y","article-title":"Molecular mechanisms of action of metformin: Latest advances and therapeutic implications","volume":"23","author":"Zhu","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4236\/pp.2024.1512025","article-title":"Metformin\u2014Pharmacokinetic and Pharmacodynamics Journey Through the Body","volume":"15","author":"Lewis","year":"2024","journal-title":"Pharmacol. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cheng, M., Ren, L., Jia, X., Wang, J., and Cong, B. (2024). Understanding the action mechanisms of metformin in the gastrointestinal tract. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1347047"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Buczy\u0144ska, A., Sidorkiewicz, I., Kr\u0119towski, A.J., and Adamska, A. (2024). Examining the clinical relevance of metformin as an antioxidant intervention. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1330797"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2147\/DDDT.S141675","article-title":"Metformin: A review of its potential indications","volume":"11","author":"Wang","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_50","unstructured":"Corcoran, C., and Jacobs, T.F. (2025). Metformin. StatPearls [Internet], StatPearls Publishing. [Updated 2023 Aug 17]."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40200-024-01406-6","article-title":"Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes","volume":"23","author":"Andraos","year":"2024","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Han, J., Li, Y., Liu, X., Zhou, T., Sun, H., Edwards, P., Gao, H., Yu, F.-S., and Qiao, X. (2018). Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193031"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bbrc.2017.08.087","article-title":"Metformin protects against retinal cell death in diabetic mice","volume":"492","author":"Kim","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00210-020-01989-w","article-title":"Metformin attenuated histopathological ocular deteriorations in a streptozotocin-induced hyperglycemic rat model","volume":"394","author":"Nahar","year":"2021","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"362ra144","DOI":"10.1126\/scitranslmed.aaf9440","article-title":"Senescence-associated secretory phenotype contributes to pathological angiogenesis in retinopathy","volume":"8","author":"Oubaha","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.1073\/pnas.1802724115","article-title":"Stimulation of AMPK prevents degeneration of photoreceptors and the retinal pigment epithelium","volume":"115","author":"Xu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","first-page":"1740943","article-title":"Metformin protects ARPE-19 cells from glyoxal-induced oxidative stress","volume":"2020","author":"Qu","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2524174","DOI":"10.1155\/2020\/2524174","article-title":"Protective effect of metformin against hydrogen peroxide-induced oxidative damage in human retinal pigment epithelial (RPE) cells by enhancing autophagy through activation of AMPK pathway","volume":"2020","author":"Zhao","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_59","first-page":"3947","article-title":"Metformin inhibits development of diabetic retinopathy through inducing alternative splicing of VEGF-A","volume":"8","author":"Yi","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_60","first-page":"5558","article-title":"Metformin inhibits development of diabetic retinopathy through microRNA-497a-5p","volume":"9","author":"Zhang","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Luodan, A., Zou, T., He, J., Chen, X., Sun, D., Fan, X., and Xu, H. (2019). Rescue of retinal degeneration in rd1 mice by intravitreally injected metformin. Front. Mol. Neurosci., 12.","DOI":"10.3389\/fnmol.2019.00102"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"32794","DOI":"10.18632\/oncotarget.15825","article-title":"Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK","volume":"8","author":"Ying","year":"2017","journal-title":"Oncotarget"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/iovs.64.15.21","article-title":"Oral metformin inhibits choroidal neovascularization by modulating the gut-retina axis","volume":"64","author":"Zhang","year":"2023","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Xiao, J.F., Luo, W., Mani, A., Barba, H., Solanki, A., Droho, S., Lavine, J.A., and Skondra, D. (2024). Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111357"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Wang, X., Liang, X., Huang, S., Wei, M., Xu, Y., Chen, X., Miao, Y., Zong, R., Lin, X., and Li, S. (2025). Metformin inhibits pathological retinal neovascularization but promotes retinal fibrosis in experimental neovascular age-related macular degeneration. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1547492"},{"key":"ref_66","first-page":"100335","article-title":"SGLT2 inhibitors: Beyond glycemic control","volume":"35","author":"Hasan","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9985836","DOI":"10.1155\/2024\/9985836","article-title":"Sodium-glucose cotransporter-2 inhibitors and cardiovascular protection among patients with type 2 diabetes mellitus: A systematic review","volume":"2024","author":"Yankah","year":"2024","journal-title":"J. Diabetes Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","article-title":"SGLT2 Inhibitors\u2014The new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: A narrative review","volume":"15","author":"Seidu","year":"2024","journal-title":"Diabetes Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00592-024-02300-6","article-title":"GLP1-GIP receptor co-agonists: A promising evolution in the treatment of type 2 diabetes","volume":"61","author":"Ciardullo","year":"2024","journal-title":"Acta Diabetol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Pescariu, S.A., Elagez, A., Nallapati, B., Bratosin, F., Bucur, A., Negru, A., Gaita, L., Citu, I.M., Popa, Z.L., and Barata, P.I. (2024). Examining the impact of ertugliflozin on cardiovascular outcomes in patients with diabetes and metabolic syndrome: A systematic review of clinical trials. Pharmaceuticals, 17.","DOI":"10.3390\/ph17070929"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e33198","DOI":"10.1097\/MD.0000000000033198","article-title":"Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"102","author":"Cheng","year":"2023","journal-title":"Medicine"},{"key":"ref_72","unstructured":"Collins, L., and Costello, R.A. (2025). Glucagon-like peptide-1 receptor agonists. StatPearls [Internet], StatPearls Publishing. [Updated 2024 Feb 29]."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ilias, I., Zabuliene, L., and Rizzo, M. (2025). GLP-1 receptor agonists in diabetes and weight loss: The double-edged sword of innovation and risks. Front. Clin. Diabetes Healthc., 5.","DOI":"10.3389\/fcdhc.2024.1530811"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cai, W., Zhang, R., Yao, Y., Wu, Q., and Zhang, J. (2024). Tirzepatide as a novel effective and safe strategy for treating obesity: A systematic review and meta-analysis of randomized controlled trials. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1277113"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"348","DOI":"10.7570\/jomes24008","article-title":"The effects of tirzepatide on lipid profile: A systematic review and meta-analysis of randomized controlled trials","volume":"33","author":"Mahar","year":"2024","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40265-023-01992-4","article-title":"Tirzepatide: A review in type 2 diabetes","volume":"84","author":"France","year":"2024","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","article-title":"Tirzepatide prevents neurodegeneration through multiple molecular pathways","volume":"22","author":"Fontanella","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_80","first-page":"459","article-title":"The effects of metformin treatment on diabetic albino rats\u2019 pancreas, liver, and kidney histology","volume":"78","author":"Almuttairi","year":"2023","journal-title":"Arch. Razi Inst."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21608\/bvmj.2022.128967.1508","article-title":"Biochemical and histopathological evaluation of the effect of metformin and metformin nanoparticles against alloxan-induced diabetes in Rats","volume":"42","author":"Salem","year":"2022","journal-title":"Benha Veter. Med. J."},{"key":"ref_82","first-page":"115","article-title":"Metformin ameliorates oxidative stress induced by diabetes mellitus and hepatocellular carcinoma in rats","volume":"9","author":"Mobasher","year":"2020","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"969","DOI":"10.4067\/S0717-95022018000300969","article-title":"Metformin pretreatment ameliorates diabetic nephropathy induced by a combination of high fat diet and streptozotocin in rats","volume":"36","author":"Dallak","year":"2018","journal-title":"Int. J. Morphol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3892\/etm.2017.4475","article-title":"Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes","volume":"14","author":"Zhang","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Dawood, A.F., Alzamil, N.M., Hewett, P.W., Momenah, M.A., Dallak, M., Kamar, S.S., Kader, D.H.A., Yassin, H., Haidara, M.A., and Maarouf, A. (2022). Metformin protects against diabetic cardiomyopathy: An association between desmin-sarcomere injury and the iNOS\/mTOR\/TIMP-1 fibrosis axis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10050984"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Yang, Z., Wang, M., Zhang, Y., Cai, F., Jiang, B., Zha, W., and Yu, W. (2020). Metformin ameliorates diabetic cardiomyopathy by activating the PK2\/PKR pathway. Front. Physiol., 11.","DOI":"10.3389\/fphys.2020.00425"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/15548627.2019.1569913","article-title":"Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway","volume":"15","author":"Niu","year":"2019","journal-title":"Autophagy"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Yan, Y., Li, T., Li, Z., He, M., Wang, D., Xu, Y., Yang, X., Bai, Y., Lao, Y., and Zhang, Z. (2021). Metformin suppresses the progress of diabetes-accelerated atherosclerosis by inhibition of vascular smooth muscle cell migration through AMPK-Pdlim5 pathway. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.690627"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1302\/2046-3758.137.BJR-2023-0384.R1","article-title":"Effects of metformin on knee joint capsule fibrosis in a diabetic mouse model","volume":"13","author":"Naito","year":"2024","journal-title":"Bone Jt. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41401-022-01031-0","article-title":"SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis","volume":"44","author":"Han","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Matthews, J.R., Schlaich, M.P., Rakoczy, E.P., Matthews, V.B., and Herat, L.Y. (2022). The effect of SGLT2 inhibition on diabetic kidney disease in a model of diabetic retinopathy. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030522"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"175521","DOI":"10.1016\/j.ejphar.2023.175521","article-title":"Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease","volume":"942","author":"Farias","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Dia, B., Alkhansa, S., Njeim, R., Al Moussawi, S., Farhat, T., Haddad, A., Riachi, M.E., Nawfal, R., Azar, W.S., and Eid, A.A. (2023). SGLT2 inhibitor-dapagliflozin attenuates diabetes-induced renal injury by regulating inflammation through a CYP4A\/20-HETE signaling mechanism. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030965"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2337\/db22-385-P","article-title":"Effects of ertugliflozin on podocyte in high-fat diet\u2013induced diabetic kidney disease model, in vivo and in vitro","volume":"71","author":"Kim","year":"2022","journal-title":"Diabetes"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"9356","DOI":"10.1080\/21655979.2021.2001240","article-title":"Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3\/caspase-1\/GSDMD pathway in pancreatic \u03b2 cells: In vitro and in vivo studies","volume":"12","author":"Liu","year":"2021","journal-title":"Bioengineered"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e019995","DOI":"10.1161\/JAHA.120.019995","article-title":"Effects of sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the presence and absence of diabetes mellitus in mice","volume":"10","author":"Croteau","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.apsb.2023.11.020","article-title":"Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis","volume":"14","author":"Zhao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Iwai, S., Kaji, K., Nishimura, N., Kubo, T., Tomooka, F., Shibamoto, A., Suzuki, J., Tsuji, Y., Fujinaga, Y., and Kitagawa, K. (2023). Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice. Biochim. Biophys. Acta Mol. Basis Dis., 1869.","DOI":"10.1016\/j.bbadis.2023.166770"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Soto-Catal\u00e1n, M., Opazo-R\u00edos, L., Quiceno, H., L\u00e1zaro, I., Moreno, J.A., G\u00f3mez-Guerrero, C., Egido, J., and Mas-Fontao, S. (2024). Semaglutide improves liver steatosis and de novo lipogenesis markers in obese and type-2-diabetic mice with metabolic-dysfunction-associated steatotic liver disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052961"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.2147\/DDDT.S384884","article-title":"Semaglutide may alleviate hepatic steatosis in T2DM combined with NFALD mice via miR-5120\/ABHD6","volume":"16","author":"Li","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.phrs.2013.07.005","article-title":"Long-term liraglutide treatment is associated with increased insulin content and secretion in \u03b2-cells, and a loss of \u03b1-cells in ZDF rats","volume":"76","author":"Robbins","year":"2013","journal-title":"Pharmacol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3892\/ijmm.2013.1453","article-title":"Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice","volume":"32","author":"Chen","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Alobaid, S.M., Alshahrani, R.M., Alonazi, A.S., Alrasheed, N.M., Alamin, M.A., Alshammari, T.K., Bin Dayel, A.F., Elnagar, D.M., Alotaibi, R.R., and Almuthnabi, L.A. (2024). Liraglutide attenuates diabetic cardiomyopathy via the ILK\/PI3K\/AKT\/PTEN signaling pathway in rats with streptozotocin-induced type 2 diabetes mellitus. Pharmaceuticals, 17.","DOI":"10.3390\/ph17030374"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Martos-Guillami, N., Vergara, A., Llorens-Cebri\u00e0, C., Motto, A.E., Mart\u00ednez-D\u00edaz, I., Gon\u00e7alves, F., Garcias-Ramis, M.M., Allo-Urzainqui, E., Narv\u00e1ez, A., and Bermejo, S. (2024). SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db\/db mice. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1415879"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"113877","DOI":"10.1016\/j.intimp.2024.113877","article-title":"GLP-1\/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K\/AKT mediated suppression of oxidative stress","volume":"146","author":"Tian","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1111\/dom.15972","article-title":"Tirzepatide, a dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic \u03b2-cells and hepatic steatosis in obese type 2 diabetic db\/db mice","volume":"26","author":"Iwamoto","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Yuan, J., Liu, W., Jiang, X., Huang, Y., Zong, L., Ding, H., Shen, X., Sun, Y., Feng, X., and Li, X. (2024). Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-66998-8"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1038\/s41467-024-50660-y","article-title":"A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma","volume":"15","author":"Jeong","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s11010-024-05066-1","article-title":"Tirzepatide alleviates oxidative stress and inflammation in diabetic nephropathy via IL-17 signaling pathway","volume":"480","author":"Yang","year":"2025","journal-title":"Mol. Cell. Biochem."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/5\/670\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:25:49Z","timestamp":1760030749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/5\/670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":109,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ph18050670"],"URL":"https:\/\/doi.org\/10.3390\/ph18050670","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}